Introduction
Integrins are a large family of glycoproteins that form heterodimeric cell adhesion and signaling receptors that mediate cell death, proliferation, migration and tissue remodeling in response to cues from the ECM. An integrin heterodimer generally consists of noncovalently linked a-and b-subunits, each subunit having a large extracellular domain, a single membrane spanning domain and a short, noncatalytic cytoplasmic tail (Hood and Cheresh, 2002) . There are 18 a and eight b subunits that form at least 25 distinct pairs of a and b heterodimers with different ligand specificity (Hood and Cheresh, 2002; Pereira et al., 2004) . In addition to controlling cell adhesion and shape, integrins also transmit signals either by physical association with several growth factor receptors or directly through recruitment of nonreceptor tyrosine kinases from the focal adhesion kinase (FAK) and Src families (Stupack and Cheresh, 2002) . The consequent downstream signals, especially via the mitogen-activated protein kinase (MAPK) and phospoinositide 3-kinase (PI3K) transduction cascades are critical for regulation of cyclin-dependent kinases (CDKs) and cell cycle progression. Furthermore, it has been reported that lack of integrin mediated adhesion to extracellular matrix proteins triggers apoptosis in endothelial cells by disrupting the integrin-mediated prosurvival signaling (Levkau et al., 2002; Ru¨egg et al., 2004) . Conversely, the appearance of unligated b-integrins has been shown to actively induce apoptosis by recruitment and activation of caspase 8 (Stupack et al., 2001) . a v b 3 integrin plays an important role in a number of physiological and pathological processes such as bone resorption, wound healing, angiogenesis, tumor invasion and metastasis (Jin and Varner, 2004; Pereira et al., 2004) . To the same extent, it has been shown that a v b 3 expression in breast and ovarian cancer, in addition to melanoma and glioma, is related to tumor progression (Janssen et al., 2002; Rolli et al., 2003) . Likewise, forced expression of the a v or the b 3 integrin subunit in a melanoma cell line increases metastatic potential (Hood and Cheresh, 2002) . In the clinical setting, the expression of a v b 3 integrin in endothelial cells within breast carcinomas has been shown to be significantly higher in tumors of patients with metastasis than in those without metastasis. This suggests that a v b 3 is an endothelial cell marker with significant prognostic value in breast carcinomas (Gasparini et al., 1998; Percheur et al., 2002) .
The RGD (arg-gly-asp) motif contained in many proteins from the ECM functions as a primary cell attachment signals. Many integrins express RGDdependent binding, for example a v b 1 , a v b 3 , a IIb b 3 , and a v b 6 (Schaffner and Dard, 2003) . There is, then, a potential for the development of an RGD-based therapeutics that could function as agonists to promote the attachment of cells and tissues to artificial matrices or as antagonists to control the nature of cell-cell and cell-ECM interactions (Craig et al., 1995; Schaffner and Dard, 2003) . Different classes of a v b 3 antagonists inhibit angiogenesis, primary tumor growth, tumor-induced hypercalcemia and colon cancer metastasis in vivo (Carron et al., 1998; Reinmuth et al., 2003) . Recent studies demonstrate that small RGD-based peptidomimetic agents, such as S-247, inhibit migration of endothelial and breast cancer cells (Harms et al., 2004; Shannon et al., 2004) .
In the breast cancer scenario, we have shown a positive correlation between a v b 3 integrin levels and overexpression of HRG a member of the epidermal growth factor (EGF)-like growth factor family associated with breast cancer tumor progression and metastasis (Tang et al., 1996; Tsai et al., 2000 Tsai et al., , 2003 Atlas et al., 2003; Menendez et al., 2003) . Moreover, we have demonstrated that forced expression of the HRG downstream effector, CYR61, is sufficient to promote acquisition of hormone independence and antiestrogen resistance in breast cancer cells (Tsai et al., 2002) . Furthermore, overexpression of CYR61 by itself is able to upregulate its own receptor a v b 3 , thus coordinating a metastatic phenotype in an autocrine fashion by activating a v b 3 -mediated proliferative (i.e. ERK1/ ERK2 MAPK) and antiapoptotic (i.e. AKT) signals (Menendez et al., 2004) . Taking this into consideration, we hypothesized that HRG may play a key role in the regulation of a v b 3 integrin expression and in its signaling functions, probably through its downstream effector, CYR61. In the present work, we have analysed cell surface expression of the RGD-binding integrins a v b 3 , a v b 5 and a v b 6 in the HRG-overexpressing breast cancer cellular models MDA-MB-231 and Hs578T. Remarkably, we observed that only a v b 3 integrin levels are decreased after blockade of HRG expression in these models, whereas no change was observed in MCF-7 cells, which do not overexpress HRG. Additionally, antisense downregulation of CYR61 expression in HRG-overexpressing breast cancer cells also decreased a v b 3 cell surface levels, indicating that the HRG-induced overexpression of a v b 3 is mediated in part if not entirely, through CYR61. Considering that the drastic effects of a v b 3 -antagonists on viability, growth, and cell cycle progression of MDA-MB-231 and Hs578T cells were dependent on the HRG-expression status of the cells, we propose that a v b 3 has a central role in the proliferation of highly invasive breast cancer models. Collectively, these results support further studies towards the development of novel therapeutics based on a v b 3 -targeting in HRG-overexpressing breast carcinomas.
Results

HRG regulates a v b 3 expression in breast cancer cells
Cell surface expression of the RGD-binding integrins a v b 3 , a v b 5 and a v b 6 was assessed by flow cytometry in MDA-MB-231 and Hs578T breast cancer cells, as well as in their respective counterparts expressing an antisense cDNA against HRG-b2 (231/ASPOOL, 231/ AS31, HS578T/AS15). Wild-type MDA-MB-231 (231/ WT) and a matched control clone transfected with an empty vector (231/VEC) show comparable levels of a v b 3 integrin, as displayed by quantitative analysis using the expression index (Geo Mean Fluorescence Â % of a v b 3 -positive cells-M1). Interestingly, the levels of a v b 3 integrin are significantly decreased in MDA-MB-231 cells expressing the antisense HRG cDNA (2.9-fold decrease in the 231/AS POOL and a six-fold decrease in the 231/AS31 cells when compared to 231/VEC cells) ( Figure 1a) . A more substantial decrease in a v b 3 levels was observed in Hs578T cells expressing the antisense HRG cDNA (Hs578T/AS15) when compared with the wild-type Hs578T cells (13.3-fold decrease) (Figure 1b) . 231/WT, 231/VEC and 231/AS31 cells showed high levels of a v b 5 , indicating that the expression of this integrin is independent of HRG in the breast cancer cells analysed. a v b 6 integrin was expressed at very low levels and it was not altered in the low-HRG-expressing clones ( Figure 1a) . Moreover, the levels of a v b 5 and a v b 6 integrins in the Hs578T cellular model were unchanged in response to blockade of HRG expression (data not shown). It is noteworthy that, among the RGD-binding integrins analysed, only a v b 3 levels are decreased in the low-HRG-expressing 231/AS31 and Hs578T/AS15 clones, suggesting an important role for a v b 3 integrin in HRG-mediated functions. WT, 231/VEC and 231/AS31 cells were cultured in the presence or absence of the a v b 3 antagonists S-247, S-106 and S-205. Interestingly, the specific a v b 3 antagonist S-247 inhibited the anchorage-dependent growth of 231/ WT and 231/VEC cells in a dose-dependent manner, but had no effect on the growth of 231/AS31 cells at identical concentrations (Figure 3 ). Control compounds (S-106 and S-205) had no effect on the growth of these cells (Figure 3) . Notable, at concentrations of S-247 higher than 0.5 mM, HRG-overexpressing breast cancer cells were rounded and clustered either floating in the medium or weakly attached to the culture support, whereas the cells expressing the antisense HRG cDNA remained as a typical epithelioid monolayer (data not shown).
To Disruption of CDKs signaling may result in cell cycle arrest, thus leading to apoptosis. A sustained cell cycle signaling presents, then, a basic mechanism by which integrins may promote cell survival and proliferation (Stupack and Cheresh, 2002) . Since we observed a specific decrease in S phase and a G1-arrest of MDA-MB-231 cells in response to the compound S-247, we . Thus, studies were aimed to assess the levels and the cellular localization of p27
Kip1 by immunoblotting, flow cytometry and fluorescent microscopy. We observed that treatment of MDA-MB-231 cells with increasing concentration of S247 resulted in a solid upregulation of p27
Kip1 levels (1.5-fold increase), as shown in Figure 6a . In contrast, the level of p27 Kip1 in the antisense cells (231/AS POOL and 231/AS31) was slightly changed after the same treatments (Figure 6a ). In accordance with these results, flow cytometric analysis showed an increase of p27
Kip1 in 231/VEC cells treated with S-247. Furthermore, when analysed in the context of cell cycle, p27
Kip1 expression was increased primarily in the G2/M-subcompartment upon treatment of 231/VEC cells with a v b 3 antagonists (two-fold increase in comparison to the untreated control), as shown in Figure 6b .
To determine the subcellular distribution of p27 Kip1 in the G2/M-phase would prevent breast cancer progression trough the G1/ S-checkpoint of the cell cycle (Figure 6c ).
HRG regulates a v b 3 integrin expression and emanating signaling through the proangiogenic factor CYR61
We have previously reported that forced expression of the proangiogenic factor CYR61 into MCF-7 cells increases a v b 3 levels and activates a v b 3 -driven cell signaling (Menendez et al., 2004) . In order to address if HRG is regulating, at least in part, a v b 3 expression through CYR61 in MDA-MB-231 cells, we have first Discussion a v b 3 integrin overexpression in tumor cells is associated with malignant progression in breast and ovarian carcinomas as well as in glioma and melanomas (Rolli et al., 2003) . In the present work, we demonstrate that HRG regulates, at least in part, the expression and the functions of the integrin receptor a v b 3 in two aggressive breast cancer cellular models (MDA-MB-231 and (Tsai et al., 2003) . The levels of a v b 3 integrin in MDA-MB-231 and Hs578T cells expressing the antisense HRG cDNA were downregulated when compared to their parental counterparts. To determine whether the link between a v b 3 and HRG was 'unique' for the a v b 3 , we tested other RGD-binding integrins, for instance a v b 5 and a v b 6 , which are expressed in these cellular models, and determined that the levels of these integrins were not modified as a result of HRG blockade. These results further confirm that a v b 3 integrin is associated with HRG expression and, in addition, that functional a v b 3 is required for the invasive phenotype of HRG-expressing cells.
It has been shown that a v b 3 integrin is involved in breast cancer progression, as indicated by the fact that this integrin is upregulated in invasive breast tumors and distant metastasis (Felding-Habermann et al., 2001) . We also showed that functional blockade of a v b 3 integrin by means of a specific antibody was able to impair Matrigel outgrowth of MCF-7 cells genetically engineered to overexpress HRG (Tsai et al., 2000) . av-integrins on endothelial cells recognize an exposed Arg-Gly-Asp (RGD) sequence within a variety of ECM proteins, including vitronectin, fibrinogen, thrombospondin, proteolysed collagen, von Willenbrand factor and osteopontin (Hynes, 1992; Stupack and Cheresh, 2002; Ru¨egg et al., 2004) . Several agents such as blocking antibodies or synthetic RGD-containing peptides directed against av-integrins have been generated and shown to inhibit in vitro endothelial tube formation or microvessel formation (Janssen et al., 2002; Buerkle et al., 2002) . To this regard, we reported that specific a v b 3 antagonists decreased the viability and growth of MCF-7 cells forced to overexpress CYR61, an angiogenic regulator that is differentially expressed in invasive human breast cancer cells (Tsai et al., 2000; Menendez et al., 2004) . Recently, we demonstrated that these antagonists can revert CYR61-induced Taxol In vivo, S-247 displays favorable pharmacokinetic properties and inhibits the formation of breast cancer metastasis to bone and lungs in mice bearing wild-type MDA-MB-435 or a GFP-expressing counterpart (435/HAL) xenografts (Harms et al., 2004; Shannon et al., 2004) . Remarkably, serum concentration of the drug reached 20 mM after administration of 100 mg/kg/day without signs of overt toxicity. Moreover, platelets aggregation was not observed in plasma concentrations exceeding 500 mM and no differences in bleeding or wound healing were observed in animals after surgery (Harms et al., 2004; Shannon et al., 2004) . These fascinating results by Harms et al and Shannon et al prove the in vivo specificity of the molecular target (a v b 3 heterodimer) and suggest that a v b 3 integrin antagonists are a suitable tool for the treatment of breast cancer patients at risk for metastatic progression.
In our study, MDA-MB-231 cells response to the a v b 3 antagonist S-247 was correlated with a decrease in cell subpopulations in the S and G2/M phases of cell cycle. However, there was no induction of apoptosis upon treatment with the a v b 3 antagonist S-247, as shown by the absence of cells with a fractional DNA content and no further caspase 3-induced cleavage of poly-ADP rybose polymerase (PARP) (data not shown). This is concomitant with findings by Cruet-Hennequart et al in a v -integrins-expressing ovarian cancer models, in which treatment with RGD-containing peptides decreased cell proliferation but did not induce apoptosis. Interestingly, S-247 did not exert the same effects in the 231/AS31 cells. Thus, the HRG expression status is indeed determining the levels of a v b 3 integrin in breast cancer cell models and dictates the response to a v b 3 antagonists.
In addition to their ability of binding and modeling the extracellular matrix, ligated integrins are able to activate cell transduction cascades influencing cell growth, differentiation, migration and apoptosis of cells (Martin et al., 2002) . Integrin-emanating signals are well defined, especially via the MAPK and PI-3 0 K pathways, which are critical for cell cycle progression and cell survival, respectively. It has been shown that ERK1 associates with a v b 3 after platelet derived growth factor addition to serum starved Swiss or NIH 3T3 fibroblasts (Roberts et al., 2003) . Additionally, we have shown that a v b 3 antagonists specifically abolished ERK1/ERK2 MAPK hyperactivation induced by the forced expression of CYR61 in MCF-7 cells without the involvement of PI-3K 0 /AKT (Menendez et al., 2004) . Therefore, we next analyzed the effects of functional blockade of a v b 3 integrin on the activation status and expression of ERK1/ERK2 MAPK and PI3K/AKT in MDA-MB-231 cells expressing graded levels of HRG. Similarly to short-term treatment, 48 h of incubation in the presence of the compound S-247 decreases overall activation status of ERK1/ERK2 MAPK in 231/VEC cells.
Interestingly, the fraction of MDA-MB-231 cells in S and G2/M phases of cell cycle was dramatically decreased after 48 h of incubation with the MEK inhibitor UO126, resembling the effects exerted by S-247 (data not shown). Neither activation status nor expression of AKT was affected upon treatment of MDA-MB-231 cells with a v b 3 antagonists. This is in concurrence with our previous findings that the a v b 3 antagonist S-247 was unable to impair CYR61-induced activation of AKT in MCF-7 cells (Menendez et al., 2004) . Coincidently, Reinmuth et al. (2003) reported that S-247 did not alter the activation status of AKT in human umbilical vein endothelial cells (HUVEC). In view of that the specific inhibitor of the p110 catalytic subunit of PI-3 0 K LY294002 was able to suppress AKT activation in CYR61 expressing MCF-7 cells (Menendez et al., 2004) , our data further confirm that the a v b 3 antagonist S-247 specifically inhibits signaling through a v b 3 in an AKT-independent mode. However, it has been reported that LM609, a functional blocking antia v b 3 antibody, is capable to decrease AKT activation and, consequently, impair CYR61-induced Taxol resistance in breast cancer cells (Lin et al., 2004) . A similar AKT-dependent impairment of a v b 3 -driven signaling was observed in ovarian cancer models, in which a vintegrins blockade, either by means of specific antibodies or by RGD-containing cyclic peptides inhibited integrin-linked kinase (ILK) and the subsequent AKT activation without alteration of the activation status of ERK/MAPK (Cruet-Hennequart et al., 2003) .
We recently showed (Menendez et al., 2004) that the small peptidomimetics a v b 3 antagonists can discriminate between the two known b 3 integrins (a v b 3 and a IIb b 3 ), then, these compounds might be preferentially blocking the signaling through the ab heterodimer rather than affecting b 3 -associated molecular effectors such as ILK and PI 0 3K. In addition, S-205, an RGD compound that binds with higher affinity to a IIb b 3 integrin did not alter the activation or the levels of ERK/MAPK. These observations strongly suggest that the nature of the signaling emanating from the integrins is determined by the type of substrate bound to them. Enforcing this hypothesis, a report by Butler et al (2003) shows that there is a differential activation of PI 0 3K upon binding of fibronectin or vitronectin to the b 3 integrin subunit. To this regard, early studies dating back to the 1980s show that detaching collagen gels from the dishes allowed their contraction by the cells into small rafts. This release of tension induced epithelial cell differentiation and inhibited mitogenesis. Later works show that release of tension by detaching collagen gels resulted in altered response of fibroblasts to growth factors, specifically decreasing PDGF-induced activation of the MAPK pathway. These results are reviewed in an intriguing discussion by Schwartz and Gingsberg (2002) , thus enforcing the role of integrins as integrators of mechanical stresses with cellular responses to soluble growth factors.
Considering that a sustained signaling emanating from b 3 -integrins is critical for the regulation of CDKs; we assessed the changes in the levels and the cellular
localization of the CDKs inhibitor p27
Kip1 in breast cancer cells upon treatment with small peptidomimetic a v b 3 antagonists. Interestingly, a significant increase in the total levels and a nuclear translocation of p27 Kip1 were seen in HRG overexpressing cells in response to the a v b 3 antagonist S-247. In accordance with our results, it has been previously reported that disruption of a v -integrin-driven signaling led to a growth arrest of ovarian cancer models, concomitantly with an increase of p27
Kip1 levels, although in an AKT-dependent fashion (Cruet-Hennequart et al., 2003) . These findings further establish the critical role of integrins as mediators of cell cycle progression of cancer cells. This regulation would be, then, accomplished by integrin-mediated modulation of the CDKs either through the Raf-MEK1/MEK2-ERK1/ERK2 or the PI 0 3K-AKT pathways. More importantly, the alterations induced by the a v b 3 antagonist S-247 in the levels and localization of p27
Kip1 were associated to the HRG-expression status of MDA-MB-231 cells, as indicated by the absence of response to a v b 3 antagonists in their HRG antisenseexpressing counterparts.
Although our current results point towards an a v b 3 -driven signaling dependence for cell proliferation and survival of naturally HRG-overexpressing breast cancer cells, the ultimate mechanism by which HRG may be regulating a v b 3 expression and function in breast cancer is still unknown. To this regard, we have previously shown that overexpression of CYR61 in MCF-7 cells is sufficient to drastically increase the levels of its integrin receptor a v b 3 and that functional blockade of a v b 3 induces a specific cytotoxic effect towards breast cancer cells engineered to overexpress CYR61. Furthermore, specific downregulation of CYR61 expression concomitantly reduced both, a v b 3 expression and HRG-enhanced cell survival (Menendez et al., 2004) . Taking this into consideration, we have analysed the levels of CYR61 in low-HRG expressing MDA-MB-231 cells, finding that blockade of HRG expression specifically reduces the levels of CYR61. In addition, our results show that antisense downregulation of CYR61 expression in MDA-MB-231 cells has a dramatic effect on a v b 3 cell surface levels; further enforcing the notion that CYR61 plays a key role in the maintenance of high levels of a v b 3 in HRG-overexpressing breast cancer cell models (Menendez et al., 2003 (Menendez et al., , 2004 . Moreover, specific downregulation of CYR61 drastically decreased MAPK activation status in MDA-MB-231 cells whereas the levels of activated and total AKT remained unaltered, thus resembling the effects of blocking HRG expression in MDA-MB-231 cells. These data are in agreement with our previous reports that a CYR61/a v b 3 molecular connection is mediating the HRG-enhanced activation of prosurvival cell signaling pathways in highly invasive breast cancer models (Tsai et al., 2000; Menendez et al., 2003 Menendez et al., , 2004 .
Previous findings from our laboratory have shown that forced expression of HRG in MCF-7 cells confers the cells a growth advantage in E 2 depleted medium and the ability to growth tumors in vivo (Tang et al., 1996) . Moreover, we have later shown that blockade of HRG in MDA-MB-231 cells inhibited cell proliferation, abolished anchorage-independent cell growth and suppressed the invasive potential of cells in vitro. In vivo, inhibition of HRG expression reduced tumor formation, size and metastatic ability of MDA-MB-231 cells (Tsai et al., 2003) . Interestingly, MCF-7 cells genetically engineered to express HRG show an increase in a v b 3 levels (Tsai et al., 2000) . These effects are mediated, at least in part if not entirely, by the downstream effector of HRG, CYR61, as we have recently reported (Menendez et al., 2004) . In the present work, we provide further evidence regarding to the regulation of the expression and activity of a v b 3 integrin in breast cancer models expressing graded levels of HRG. Our results demonstrate that HRG specifically regulates expression of a v b 3 in the tumorigenic and metastatic breast cancer cellular models MDA-MB-231 and Hs578T. This is 'unique' to a v b 3 since the levels of other a v -integrins such as a v b 5 and a v b 6 remain unaltered upon blockade of HRG expression. Of interest, the HRG-negative MCF-7 cells express high levels of a v b 5 integrin, which are not modified by the forced expression of HRG (data not shown). We also present evidence that functional blockade of a v b 3 integrin dramatically decreased HRG-overexpressing breast cancer cells viability, anchorage-dependent cell growth and the fraction of cells in S and G2/M compartments of cell cycle. In addition, our results indicate that a v b 3 is regulating cell cycle progression of breast cancer cells preferentially via the Raf-MEK1/MEK2-ERK1/ERK2 pathway. Moreover, the requirement of an activated a v b 3 integrin for the proliferation of HRG-overexpressing breast cancer models (Tsai et al., 2000) is further confirmed by our observations that functional blockade of a v b 3 led to an increase of the levels and nuclear translocation of the CDKs inhibitor p27 Kip1 . Furthermore, the fact that the antisense downregulation of CYR61 expression specifically decreased a v b 3 expression levels in MDA-MB-231 cells strongly suggests that the proposed HRG/a v b 3 crosstalk is mediated, in part if not entirely, through the HRG downstream effector, CYR61. In accordance with these results, we have previously reported that CYR61 can regulate the levels of a v b 3 expression as well as breast cancer cell sensitivity to taxol-induced cell damage in an HER2/neu-independent fashion (Menendez et al., 2004) . CYR61 is also an important growth regulator in endothelial cells, mainly through its binding with the cell surface integrins a v b 3 and a 6 b 1 (Leu et al., 2002 (Leu et al., , 2004 . Since integrin ligation is required for endothelial cells responses to most proangiogenic factors (Stupack and Cheresh, 2003) , it is reasonable to offer a model in which the HRG/CYR61/a v b 3 molecular connection may be orchestrating breast tumorigenesis and progression in at least two concerted modes: (1) by regulating endothelial cells survival and recruitment during tumor neovascularization in a paracrine fashion through an a v b 3 -dependent mechanism; and (2) by promoting breast cancer epithelial cell proliferation in an autocrine/paracrine manner either by increasing the activity of other growth factors (i.e. EGFR), or by enhancing breast cancer epithelial cell a V b 3 and Heregulin in breast cancer L Vellon et al survival and chemoresistance through activation of a v b 3 -driven prosurvival signaling pathways (ERK1/ ERK1 MAPK and/or AKT) as we previously described (Menendez et al., 2003 (Menendez et al., , 2004 (Figure 8 ).
In conclusion, the present data demonstrate, to the best of our knowledge, for the first time that a v b 3 integrin has a crucial role in the HRG-associated invasive phenotype of breast cancer cells. In addition, we present evidence of an HER2/neu-independent CYR61-mediated cross-regulation between HRG, a growth factor that is known to induce tumorigenicity and a v b 3 , an integrin known to be a poor prognostic factor in breast cancer, thus providing a relevant therapeutic avenue for the treatment of breast carcinomas. Moreover, these findings encourage further studies concerning the use of integrin antagonists as dual therapeutic agents for breast cancer treatment, targeting both, endothelial and tumor cells.
Materials and methods
Cell culture
Human breast cancer cells MDA-MB-231 and Hs578T were maintained in monolayer in IMEM medium supplemented with 5% FBS at 371C in a humidified 5% CO 2 atmosphere. Blockade of HRG expression in MDA-MB-231 cells was achieved as previously described (Tsai et al., 2003) . Briefly, the eukaryotic expression vector pRC/CMV carrying the HRG-b2 cDNA (amino acids 1-426) in an antisense direction was transfected into MDA-MB-231 cells. Several clones were then isolated and their HRG expression status at the mRNA and protein levels further analysed by RNAse protection assay and Western Immunoblotting, respectively. Matching control clones transfected with the empty vector (231/VEC) were also generated and characterized. Hs578T cells were similarly transfected with the HRG-b2 cDNA in an antisense orientation and an antisense clone (Hs578T/AS15) and matched controls were used along with the MDA-MB-231 cell derivatives. To block CYR61 expression, an eukaryotic expression vector pcDNA3.1/zeocine (À) was constructed with the antisense orientation of the full-length CYR61 cDNA as previously described (Menendez et al., 2004) , and subsequently transfected into the HRG-overexpressing MDA-MB-231 cells. Several CYR61 antisense clones (MDA/CYR61-AS) as well as matched controls expressing an empty vector were isolated (MDA/CYR61-ASV). Two MDA/CYR61-AS representative clones (MDA/ASCYR61-5 and MDA/ASCYR61-8) were characterized further.
Antibodies and reagents
Six a v b 3 small peptidomimetics containing the RGD (arg-glyasp) motif were developed based on a structure/activity-based medicinal chemistry rationale as previously described (Meyer et al., 2001; Griggs et al., 2001) and kindly provided by Dr. Griggs (Pfizer Corporation, St Louis, MO, USA). 2 mM stock solutions were prepared and stored at 41C. Monoclonal antibodies against integrins a v b 3 (LM 609), a v b 5 (P1F6) and Kip1 (clone C-19) and the anti-CYR61 (clone C-20) were purchased from Santa Cruz (CA, USA).
Flow cytometry evaluation of RGD-binding integrins
Breast cancer cells were incubated until 70% of confluence was reached. Cells were then harvested by scrapping, counted and incubated with the stated antibodies against the RGD-binding integrins a v b 3, a v b 5 and a v b 6 (3 mg/500 Â 10 3 cells/100 ml) during 1 h at 41C. After that, cells were washed twice with cold PBS þ 1% FBS, and incubated with a FITC-conjugated secondary antibody during 30 min at 41C. Cells were then analyzed in a FACScalibur flow cytometer (Becton Dickinson). Cell Quest software (Becton Dickinson) was used for data acquisition and analysis.
Cell viability and proliferation studies
Cell viability was assessed using the MTT assay using the CellTiter 96 s Non-Radioactive Cell Proliferation assay (Promega Corporation, WI, USA). Briefly, MDA-MB-231 cells were seeded at 3 Â 10 3 cells/well in 96-well plates and allowed to attach. After 24 h, the medium was removed, and fresh medium along with the a v b 3 antagonists at concentrations ranging from 0 to 4 mM was added to the cultures. When untreated controls reached confluency, the medium was aspirated carefully and the MTT dye solution added. After 3-5 h of incubation at 371C, the reaction was stopped with the 'Solubilization/Stop' buffer. Absorbance at 570 nm was measured following overnight incubation at 371C.
Anchorage-dependent cell growth was assessed as follows: cells were seeded (40 Â 10 3 cells/well in 24-well plates), allowed to attach and then treated with the RGD-based peptidomimetic compounds S-247, S-205 and S-106 at concentrations from 0 to 1 mM for 48 h. After treatment, the attached and detached fractions of cells were counted using a Coulter cell counter.
p27
Kip1 and DNA content analysis by flow cytometry MDA-MB-231 breast cancer cells were seeded in Petri dishes and treated with up to 1 mM of the RGD compounds S-247 and S-205. Cells were then harvested and p27 Kip1 and DNA content was analysed after 24 and 48 h of treatment. For p27 Kip1 detection, cells were harvested, fixed in paraformaldehyde 1% for 15 min and stored in ethanol 70% at À201C. After fixation, cells were permeabilized with PBS þ 0.25% Triton X-100 for 10 min, washed with cold PBS þ 1% FBS and incubated with an anti p27
Kip1 antibody for 2 h at room temperature. Upon incubation, the samples were washed twice and incubated with an FITC-conjugated secondary antibody, washed again, treated with RNAse A and stained for DNA analysis as indicated. For cell cycle studies, treated cells were fixed in ethanol 70% and stored at À201C. Fixed cells were then washed in cold PBS þ 1% FBS, and incubated with RNAse A (0.2 mg/ml) in PBS at 371C for 20 min. Propidium Iodide was then added to the cell suspension to reach a final concentration of 20 mg/ml in PBS. After that, cells were incubated 30 min at RT in the dark. Cell Quest software (Becton Dickinson) was used for data acquisition and ModFit software for cell cycle analysis.
Immunoblotting analysis of ERK1/ERK2 MAPK, p-ERK1-ERK2 MAPK, AKT, pAKT and p27
KIP1
Overnight serum-starved cells were treated with a v b 3 antagonists during 48 h. After treatment, cells were harvested, washed twice with PBS, and lysed with buffer (20mM Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1%Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM b-glycerolphosphate, 1 mM Na 3 VO 4 , 1 mg/ml Leupeptin, 1 mM phenylmethylsulfonylfluoride) for 30 min on ice. The lysates were then cleared by centrifugation (15 min at 14 000 r.p.m.À41C). Protein concentration was determined using the Pierce protein assay kit (Rockford, IL, USA). Equal amounts of protein (20 mg) were resuspended in 5 Â Laemli buffer (10 min at 701C), resolved by electrophoresis on 10% SDS-PAGE, and transferred onto nitrocellulose membranes (Amersham Biosciences). The membranes were then blocked with TBS-T (25 mM Tris-HCl, 150 mM NaCl (pH 7.5), and 0.05% Tween 20) containing 5% (w/v) non-fat dry milk and incubated overnight at 41C with specific antibodies. After incubation, the membranes were washed in TBS-T and HRP-conjugated anti-rabbit, anti-mouse or anti-goat were added for 1 h as secondary antibodies. Immunodetection was performed using the Western Lightingt chemiluminescence reagent from Perkin Elmer (Boston, MA, USA). Quantitative analysis of protein content was carried out using the Scion Image software (Scion Corporation).
Immunobloting analysis of CYR61 in cell supernatants
Subconfluent human breast cancer cells MDA-MB-231 and derivatives expressing the antisense orientation of the HRG-b2 cDNA were maintained in serum-free media for 48 h. The conditioned media was collected and, concentrated 20 Â and resolved by 10% Tris-glycine SDS-PAGE. The separated proteins were then transferred onto a Hybond enhanced chemoluminiscence nitrocellulose membrane (AmershamPharmacia). The membrane was blocked overnight at 41C with 5% (w/v) BSA in Tris buffered saline containing 0.05% Tween 20 (TSBT), and then incubated with a rabbit anti-CYR61 polyclonal antibody (1 : 2000 dilution) for 1 h at room temperature. After three washes with TBS-T, the blot was incubated with a 1 : 10 000 dilution of horseradish peroxidaselinked donkey antirabbit IgG secondary antibody. The CYR61 protein was detected by the enhanced chemoluminiscence reaction using Hyperfilm (Amersham-Pharmacia). Immunoblotting analysis of CYR61 in cell lysates was performed as indicated above.
Immunofluorescence
p27
Kip1 cellular localization was assessed by immunofluorescence as follows. MDA-MB-231 cells were seeded in eight-well Labtek chambers and incubated in the presence or absence of a V b 3 antagonists for 48 h. The cells were then fixed in 4% paraformaldehyde at 41C and permeabilized with PBS-0.2% Triton X-100 for 10-15 min. After blocking overnight with PBS þ 10% Horse Serum, the cells were rinsed with cold PBS, and incubated with an anti-p27
Kip1 antibody for 2 h at room temperature. A secondary FITC-conjugated antibody was used as a detection antibody. After exhaustive washings, the slides were mounted in Vectashield s mounting medium with DAPI (Vector Laboratories, CA, USA) and analysed using a Nikon Eclipse E800 microscope.
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